Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

297
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
297
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

463
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
463
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

657
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
657
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

1.0K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.0K
Elimination Kinetics: First-Order and Zero-Order01:05

Elimination Kinetics: First-Order and Zero-Order

2.6K
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is a drug's half-life, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing.

Clinical pharmacology and therapeutics·2026
Same author

Deep learning-powered quantification of endocrine cells and CD3<sup>+</sup> T cells in the natural history of type 1 diabetes.

Diabetologia·2026
Same author

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug Development.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy.

Pharmacotherapy·2026
Same author

Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations.

PloS one·2026
Same author

Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia.

Antimicrobial agents and chemotherapy·2025
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

672

Analyzing Pharmacodynamic Count Data That Rapidly Decrease to Zero.

Walter M Yamada1, Alan Schumitzky1, Alona Kryshchenko2

  • 1Children's Hospital Los Angeles, Los Angeles, California, USA.

CPT: Pharmacometrics & Systems Pharmacology
|December 4, 2025
PubMed
Summary
This summary is machine-generated.

Accurate modeling of infection rebound after drug treatment requires careful consideration of count data distribution. Assuming Poisson for low counts and normality for high counts best predicts treatment efficacy and lack of rebound.

Keywords:
PmetricsPoisson distributioncolony‐forming unitcount datanonparametric maximum likelihood

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.2K

Related Experiment Videos

Last Updated: Jan 9, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

672
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.2K

Area of Science:

  • Pharmacokinetics/Pharmacodynamics (PK/PD)
  • Statistical Modeling
  • Infectious Disease Dynamics

Background:

  • Accurate estimation of infection rebound is crucial for evaluating drug efficacy.
  • Count data in antimicrobial studies often exhibit a high-to-zero pattern.
  • Existing statistical methods may not optimally handle this data characteristic.

Purpose of the Study:

  • To develop and evaluate a framework for maximum likelihood analysis of count data in drug comparison studies.
  • To compare different probability distribution assumptions (Poisson, Normal) for modeling infection rebound.
  • To identify the optimal statistical approach for predicting treatment outcomes.

Main Methods:

  • Simulated Colony Forming Unit (CFU) profiles using an Emax inhibitory PK-PD model.
  • Optimized model parameters based on four different probability distribution assumptions for CFU counts.
  • Assessed prediction accuracy for infection rebound (CFU ≥ 10 at 24h post-treatment).

Main Results:

  • The strategy assuming Poisson distribution for low CFU counts (<128) and normal distribution for higher counts provided the best prediction of rebound percentage.
  • Modeling with Poisson distribution at low counts accurately reflects the true proportion of no rebound.
  • Assuming normality for counts ≥128 is reasonable, while censoring data leads to biased models.

Conclusions:

  • A hybrid approach combining Poisson and Normal distributions is recommended for analyzing count data that drops to zero.
  • This framework improves the prediction of infection rebound and treatment efficacy.
  • Proper statistical modeling is essential for robust interpretation of antimicrobial study results.